ArticleFrontiers in immunology2026
Case Report: Sequential eculizumab and belimumab in a paediatric patient with lupus nephritis and immune complex-mediated renal microangiopathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal microangiopathy is a severe complication of systemic lupus erythematosus, particularly when mediated by immune complex deposition. The optimal management of paediatric immune complex-mediated renal microangiopathy with rapid clinical deterioration remains unclear, and data on sequential complement and B-cell targeted therapy in this setting are scarce. Case summary: A previously healthy 14-year-old Chinese male patient presented with joint pain and generalised oedema. He was diagnosed with systemic lupus erythematosus, and the renal biopsy confirmed lupus nephritis (IV combined with V type) and immune complex-mediated renal microangiopathy (IC-RMA). The patient received a first-line intensive treatment regimen and showed an insufficient clinical response. Considering the severity and suspected complement-driven injury, we then initiated eculizumab, and his joint pain, generalised oedema, haematuria, proteinuria, and SLEDAI score were all improved. Belimumab was subsequently administered after 3 months of eculizumab therapy, and there was no recurrence for 1 year later. Conclusion: Sequential eculizumab and belimumab may be potential alternatives for selected paediatric patients with IC-RMA, although further studies are needed to confirm their efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.